CAMBRIDGE, Mass., Oct. 14, 2008 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that new data from several preclinical studies evaluating the company's innovative small molecule drug candidates -- oral Hsp90 inhibitor IPI-493 and oral Hedgehog signaling pathway inhibitor IPI-926 -- will be presented during the 20th AACR-EORTC-NCI Symposium on "Molecular Targets and Cancer Therapeutics," being held in Geneva, Switzerland from October 21 through October 24, 2008.
The schedule of presentations for Infinity's drug candidates is as follows:
Wednesday, Oct. 22, 2008: 12:00 - 2:55 p.m. Poster Session Title: Heat shock proteins Poster Presentation Title: IPI-493, a potent, orally available Hsp90 inhibitor of the ansamycin class Poster number: 153 Presenter: John Lee, Ph.D., Director, Pharmaceutical Development, Infinity Location: Poster Hall Wednesday, Oct. 22, 2008: 12:00 - 2:25 p.m. Poster Session Title: Heat shock proteins Poster Presentation Title: Comparison of the cellular and biochemical properties of ansamycin and non-ansamycin based Hsp90 inhibitors Poster number: 148 Presenter: Christian C. Fritz, Ph.D., Senior Director, Cancer Cell Biology, Infinity Location: Poster Hall Friday, October 24, 2008: 12:00 - 2:00 p.m. Poster Session Title: Signal transduction modulators Poster Presentation Title: Activity of IPI-926, a novel inhibitor of the HH pathway, in subcutaneous and orthotopically implanted xenograft tumors that express SHH ligand Poster number: 570 Presenter: Jens Sydor, Ph.D., Director, Drug Metabolism and Pharmacokinetics, Infinity Location: Poster Hall
About Infinity Pharmaceuticals, Inc.
Infinity is an innovative cancer drug discovery and development company that is seeking to discover, develop, and deliver to patients best-in-class medicines for the treatment of cancer and related conditions. Infinity combines proven scientific expertise with a passion for developing novel small molecule drugs that target emerging cancer pathways. Infinity's two most advanced programs in Hsp90 inhibition and Hedgehog signaling pathway inhibition are evidence of its innovative approach to oncology drug discovery and development. For more information on Infinity, please refer to the company's website at http://www.infi.com.